In this study, we analysed the very long-term impact of the presence of NPM1 and/or FLT3 mutations in a large cohort of AML patients, homogeneously treated in the pre-midostaurin era with a program different from classical 3+7, whose overall intensity was higher. Here, NPM1 is linked to acute myeloid leukemia.